Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease Simufilam continued to demonstrate an overall favorable safety profile Cassava’s Alzheimer’s disease development program with simufilam will be completely discontinued by the end of Q2 2025 March 25, 2025 -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on

Our analysis of February data reveals key trends in global preclinical-stage biopharmaceutical financing. For contextual understanding, we recommend beginning with the following article. Highlights of Financing and Strategic Collaborations in the Preclinical Biopharmaceutical Sector: February 2025(1) 12.Harbour BioMed and Insilico Medicine Form Strategic Partnership to Advance AI-Driven Antibody Discovery and Development Harbour BioMed and Insilico Medicine have established a strategic partne

As global healthcare continues to demand innovative therapies, February 2025 has emerged as a critical period witnessing the robust growth of the biopharmaceutical sector. This month has seen significant capital inflows supporting preclinical-stage research and multiple high-impact collaborations and licensing deals. For example, CSPC Pharmaceutical, through its subsidiary Megalith Biopharmaceutical, transferred the overseas rights of its ROR1-targeting antibody-drug conjugate (ADC), SYS6005, to

February 2025 brought a wave of exciting news for innovators in the global healthcare industry. From breakthrough therapies for neuropsychiatric disorders to cutting-edge advancements in ENT surgical devices, a series of startups have laid a solid foundation for future growth through successful financing activities. These companies have not only attracted significant capital but also showcased the most forward-thinking technologies and solutions in their respective fields. In this era of both ch

In recent years, GLP-1 receptor agonists have emerged as a key therapeutic category in the field of metabolic diseases due to their dual benefits of glycemic control and weight loss. Novo Nordisk’s semaglutide, available in both oral and injectable formulations, has rapidly positioned itself as a leading contender for the title of "global best-selling drug," propelling the company to the top of Europe's pharmaceutical market capitalization rankings. Meanwhile, small-molecule GLP-1 receptor agoni

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s unwavering commitment to patient impact, “Breaking Through Defenses, Delivering Hope” March 25, 2025 -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company’s new name: Ernexa TherapeuticsSM (NASDAQ: ERNA). The new

March 25, 2025 -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), ”), a leader in RNA-based therapeutics, announced today the successful completion of a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101,an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites Trial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology March 25, 2025 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cance

Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib Strong correlation between C-peptide increase and HbA1c reduction (r = -0.73, p<0.0001) across all dosing groups (n=23) support the proposed mechanism of beta cell restoration Best response observed in prespecified, beta-cell deficient patients on one or more antihyperglycemic agents at baselin

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs March 24, 2025 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it initiated a pivotal phase 3 psoriasis study of its oral drug Piclidenoson with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) -